[HTML][HTML] CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed …
JE Lancet, GL Uy, JE Cortes, LF Newell… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
JE Lancet, GL Uy, JE Cortes, LF Newell, TL Lin, EK Ritchie, RK Stuart, SA Strickland…
Journal of Clinical Oncology, 2018•ncbi.nlm.nih.govPurpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin
that delivers a synergistic 5: 1 drug ratio into leukemia cells to a greater extent than normal
bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure
in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin
chemotherapy (7+ 3 regimen) in older patients with newly diagnosed secondary acute
myeloid leukemia (sAML).
that delivers a synergistic 5: 1 drug ratio into leukemia cells to a greater extent than normal
bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure
in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin
chemotherapy (7+ 3 regimen) in older patients with newly diagnosed secondary acute
myeloid leukemia (sAML).
Abstract
Purpose
CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5: 1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+ 3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML).
ncbi.nlm.nih.gov